이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pulmatrix 배당금

배당금 기준 확인 0/6

Pulmatrix 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.42
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PULM 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PULM 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Pulmatrix 시장 대비 배당 수익률

PULM 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PULM)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Pharmaceuticals)	2.2%
3년 후 애널리스트 예측 (PULM)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PULM 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PULM 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PULM 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: PULM 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Pulmatrix 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기